EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
about
Targeting EZH2 in cancerEZH2 in normal hematopoiesis and hematological malignanciesEZH2 in Bladder Cancer, a Promising Therapeutic TargetEpigenetics in normal and malignant hematopoiesis: An overview and update 2017.EZH2: not EZHY (easy) to deal.A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Regulation and Role of EZH2 in CancerEZH2 as a potential target in cancer therapy.RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndromeHIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.Clonogenic multiple myeloma cells have shared stemness signature associated with patient survivalThe histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.Aberrant histone modification in CD19+ B cells of patients with chronic lymphocytic leukemiaIntegrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing.Histone lysine demethylases as targets for anticancer therapy.Novel targets for natural killer/T-cell lymphoma immunotherapy.Therapeutic Options for Aggressive T-Cell Lymphomas.EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype.Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer.JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic functionMYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.Gene-body hypermethylation controlled cryptic promoter and miR26A1-dependent EZH2 regulation of TET1 gene activity in chronic lymphocytic leukemia.Expression of EZH2 is associated with poor outcome in colorectal cancer.Ezh2 promotes clock function and hematopoiesis independent of histone methyltransferase activity in zebrafish.Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.EZH2: a potential new target in T-cell lymphoma?EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.Loss of maternal EED results in postnatal overgrowth.LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
P2860
Q26769027-A4A365D0-1B8B-48E2-9581-5E3F0EF53F3EQ26779821-5A951D2D-8DF2-486C-81E7-820EB2226A5EQ28082054-B2863D29-490E-436D-95FA-8AF46A61033FQ33607609-13FAC5EC-D3AB-4374-8456-0B4D05B33BEBQ33610902-2CCAF72E-9096-431D-AE3C-723C85F95481Q33626131-ED81EBBC-69CE-492E-85F7-65B59DC6A6E0Q33914216-651C739F-0425-4C29-ACCF-60A803D7465FQ34043370-F6A7A837-A810-4405-B2EB-7DA1D39FC34FQ35222823-20C201EB-3820-4FD2-957F-129D803DD89DQ36259257-25520999-BBBD-402B-BF11-13EC1DDF10C9Q36946728-07D34DE1-D807-4FF4-8278-CF4FEE310910Q37065194-5FCC350F-4CEC-44B8-BDC1-859F232313C8Q37207661-31389C20-2CC1-43C8-8B50-437100DB0EA7Q37392612-D4B141E9-C404-40BB-B621-D50F046510A0Q37669493-8719B5A2-55EB-4D4F-BA9C-24B5579F27F2Q37697207-7470E7A2-ACEC-413C-A2EB-E35C01758EEEQ38162717-39EAE906-7F64-4E6B-98B3-828ACD66E84BQ38661106-84D9A4D8-32FD-41EB-9ED6-3A30652AB57BQ38675843-EEBA53FA-8EC9-4FE0-94EF-BACB3D9038F3Q38761793-652C1AA6-B794-4869-A3F6-B66446626337Q38906678-D571D27E-EDC0-4323-A287-D9581AD26A23Q38941606-DB168544-92A6-4F2F-BEEF-151B30B45DDDQ38961785-2FF70254-50A3-4920-B311-392106270D5CQ41083925-0893CD71-5D45-4F3B-A660-7BBBDD29757BQ41576148-04228FF0-3BFF-4E4B-B801-1664226C6148Q45742884-B954700E-A6FC-40CF-A4C7-B88A9B5F29E1Q47134267-A3D8D78F-281D-4185-A81A-3B94F1AF5CFFQ49768936-83F44F1F-93C1-4979-AA53-87013E040EFCQ49977670-3F4630A3-2F03-471D-A8FA-EF7FC9ABCC49Q50071606-AA828463-EC2C-4A2B-9AEA-B4F74F339A91Q52349529-044D5DA9-79FF-4B73-85DA-8593145AAB37Q53003254-777FA4EB-B2E0-42A0-BACF-142405D5030CQ55018505-51EF2844-E447-4558-9572-250A2A87A575Q55646870-44F33278-EF02-4455-A41D-4959E9D737C4Q58796912-26C36284-6E31-4DA0-A9AB-8147A1082C1A
P2860
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
EZH2 overexpression in natural ...... ne methyltransferase activity.
@en
EZH2 overexpression in natural ...... ne methyltransferase activity.
@nl
type
label
EZH2 overexpression in natural ...... ne methyltransferase activity.
@en
EZH2 overexpression in natural ...... ne methyltransferase activity.
@nl
prefLabel
EZH2 overexpression in natural ...... ne methyltransferase activity.
@en
EZH2 overexpression in natural ...... ne methyltransferase activity.
@nl
P2093
P1433
P1476
EZH2 overexpression in natural ...... ne methyltransferase activity.
@en
P2093
Baohong Lin
Chonglei Bi
Gaofeng Huang
Jim Liang-Seah Tay
Norio Shimizu
Shaw-Cheng Liu
P304
P356
10.1182/BLOOD-2012-08-450494
P407
P577
2013-03-25T00:00:00Z